7:00 am Check-In & Coffee
8:00 am Opening Remarks
Revitalizing Progress of Allogeneic Approaches by Managing Investor Expectations & Demonstrating Key Clinical Data
8:10 am Industry Leaders’ Fireside Chat: Achieving Allogeneic Product Success by Aligning Innovation with Investor Expectations
Synopsis
An interactive panel discussion from the industry leaders of the field to set the scene on the allogeneic cell therapy space.
Ask your questions live to understand the expert’s thoughts on key topics including:
- Evaluating key success factors for allogeneic therapies and how they differ from autologous approaches
- Discussing the role of clinical trial outcomes in shaping investor confidence and the future of allogeneic products
- Discussing how to best communicate and showcase positive allogeneic therapy results
- Sharing the latest advancements in the space and how that will shape the future of allogeneic therapies
9:00 am Session Reserved for ScaleReady
9:30 am Unleashing the Promise of Cell Therapy for Cancer & Autoimmune Diseases
Synopsis
- Highlighting how Atara Bio is innovating next-generation CAR-Ts with the only allogeneic T-cell platform with an approved product
- Focusing on how EBV T-cell biology and novel CAR technologies can address the current limitations of autologous and other allogeneic CAR approaches
- Describing ATA3219, Atara Bio’s allogeneic CAR-T targeting CD19, for the potential treatment of SLE and NHL
10:00 am Highlighting Key Clinical Readouts in the Application of NK Cells to Haematological Malignancies to Further NK Therapy Development
Synopsis
- Discussing key successes thus far in clinic of Senti-202 in AML
- Sharing lessons learned and next steps
10:30 am Morning Break & Speed Networking
Synopsis
As the allogeneic community is reunited, this valuable session will ensure you can reconnect with your peers in the room to make new and lasting connections. Also, don’t forget to enjoy some refreshments before we split off into the two different tracks: Preclinical and Manufacturing & Process Development
Preclinical
Highlighting Key Factors in the Design of Allogeneic Products to Minimize Adverse Effects of Allotransplantation
11:30 am Developing Progenitor T-Cell Therapy to Maintain Effective & Diverse TCRs while Ensuring Safety
Synopsis
- Producing T-cell progenitors (ProTcell) with a feeder cell-free manufacturing process designed to generate clinical batches
- Infusing ProTcells that get educated and develop in the host thymus to participate in immune response without generating GvHD
- Characterizing ProTcells and T-cells generated after further maturation in artificial thymic organoids or in vivo
Achieving Reliable & Effective Genetic Engineering to Transform Allogeneic Cells
12:00 pm Leveraging Cell Engineering to Maximize Anti-Tumor Properties of Allogeneic Cells
Synopsis
- Intellia’s differentiated allogeneic platform has shown key characteristics in in vitro assays and in vivo mouse models
- Approach expected to be compatible with standard lymphodepletion
- Allogeneic platform is readily deployable for TCR-T and CAR-T cell therapy
Manufacturing & Process Development
Leveraging Automation to Reduce Cost of Goods & Error in the Process
11:30 am Unlocking Closed Manufacturing to Boost Compliance & Minimize Contamination
Synopsis
- Explore the critical requirements for implementing closed manufacturing systems to enhance product integrity and reduce contamination risks
- Understand the feasibility of closed manufacturing processes, including technological advancements and operational considerations in the transition
12:00 pm Panel Discussion: Understanding When & How to Implement Automation into the Process for a Seamless Transition into Automated Manufacturing
Synopsis
- Analyze the key factors that determine the optimal timing for integrating automation into manufacturing processes, focusing on efficiency, scalability, and cost-effectiveness
- Explore different automation technologies available for allogeneic cell manufacturing
- Discuss best practices for implementing automation, including staff training, system integration, and ongoing maintenance
12:30 pm Private Lunch Hosted by Equashield
Synopsis
Please contact [email protected] for inquiries
Achieving Reliable & Effective Genetic Engineering to Transform Allogeneic Cells
1:30 pm How to Listen to Cells: Secretomics for Cutting-Edge Insight into Cell Function in Cancer & Immune Disorders
Synopsis
- Leveraging single cell secretomics to gain a deeper understanding of cell behaviour
- Using secretomics at mass scale in target discovery and validation, quality assurance of cells, and patient stratification
2:00 pm Leveraging NGS for Accurate Characterization of Cell Drug Products
Synopsis
- Highlighting the role of NGS in verifying the accuracy of vector sequences and preventing mutation issues
- Emphasizing the importance of NGS in ensuring the safety and efficacy of cell therapy products by checking the accuracy of CAR sequences
Refining Processes for Scalable & High-Quality Allogeneic Production
1:30 pm Off-the-Shelf Allogeneic Cell Therapy in Autoimmune Diseases & Cancers
Synopsis
- Optimizing γ CAR-T manufacturing processes to produce ~1,000 doses with high purity and CAR expression
- Discussing how γ CAR-T products with armored CAR design achieves comparable tumor serial killing in vitro and superior tumor clearance in vivo compared to γγ CAR-T
- In vivo CAR-T therapy by T cell-targeted LNP delivery achieves complete Nalm-6 tumor control in a mouse model
2:00 pm Roundtable Discussion: Optimizing Product Formulation & Fill Finish to Ensure a High Quality End Product
Synopsis
- Discussing the latest technologies allowing for better product formulations that maintain cell viability and potency through storage and administration
- Strategies to enhance fill-finish processes to minimize contamination risks and ensure consistent quality for each dose
2:30 pm Afternoon Break & Poster Session
Sharing our Current Understanding of Allogeneic Therapies Beyond Haem Malignancies to Harness the Full Potential of Universal Cell Therapies
3:30 pm Developing Allo-CAR-Ts Against Solid Tumors & Autoimmune Indications
Synopsis
- Discussing current clinical programs in solid tumors and several autoimmune conditions
- Leveraging armoring technologies to breach into solid tumors
4:00 pm Using Neural Stem Cell Delivered Oncolytic Viruses for the Treatment of Glioma & Ovarian Cancer
Synopsis
- Discussing the unique approach of using tumor-tropic NSCs as delivery vehicles of oncolytic viruses
- Discuss current multi-dose, multi-site glioma clinical trial and planned 2026 ovarian cancer clinical trials using this approach
- Manufacturing overview